Back to search

Article

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.

2023-11-14

Abstract excerpt

<title>Abstract</title> <p>Background The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating natural killer (TI-NK) cells can predict the efficacy of HER2-targeted antibodies independently from clinicopathological factors in primary HER2-positive breast cancer patients....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4b1eab0a-3f8b-5320-aed0-2510c2fbe09f
DOI
10.21203/rs.3.rs-3575859/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.DOI 10.21203/rs.3.rs-3575859/v1
Select a neighboring publication to make it the new centre.